Determination of the pathogenicity of a novel COL4A5 missense variant by CRISPR-Cas9 in kidney podocytes.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  American journal of translational research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 34540022PMCID PMC8430118
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SGLT2 inhibitors - a potential treatment for Alport syndrome.

  2020cited by this paper
• Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome.

  2018cited by this paper
• Urine‐derived podocytes‐lineage cells: A promising tool for precision medicine in Alport Syndrome

  2018cited by this paper
• Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group.

  2018cited by this paper
• A review of clinical characteristics and genetic backgrounds in Alport syndrome

  2018cited by this paper
• Phenotype variability in a large Spanish family with Alport syndrome associated with novel mutations in COL4A3 gene

  2017cited by this paper
• Functional assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in X-linked Alport syndrome

  2017cited by this paper
• End-stage renal disease in Japanese children: a nationwide survey during 2006–2011

  2015cited by this paper
• KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy

  2015cited by this paper
• X-linked Alport syndrome caused by splicing mutations in COL4A5.

  2014cited by this paper
• End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.

  2014cited by this paper
• Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain.

  2014cited by this paper
• Clinical utility gene card for: Alport syndrome – update 2014

  2014cited by this paper
• Alport syndrome—insights from basic and clinical research

  2013influential reference
• Women and Alport syndrome

  2011influential reference
• Clinical utility gene card for: Alport syndrome

  2011cited by this paper
• Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis.

  2009cited by this paper
• RNA quality control in eukaryotes.

  2007cited by this paper
• Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples.

  2007cited by this paper
• Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts.

  2005cited by this paper
• X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.

  2003cited by this paper
• Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome

  2002cited by this paper
• X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.

  2000cited by this paper
• The clinical spectrum of type IV collagen mutations.

  1997cited by this paper
• A mutation causing Alport syndrome with tardive hearing loss is common in the western United States.

  1996cited by this paper

• The 2019 and 2021 International Workshops on Alport Syndrome

  2022cites this paper
• Identification of Four Novel COL4A5 Variants and Detection of Splicing Abnormalities in Three Chinese X-Linked Alport Syndrome Families

  2022cites this paper